Published in the Journal of Clinical Oncology, results from the Phase II trial, MM-013 show that pomalidomide (Imnovid®) in combination with low-dose dexamethasone is effective in relapsed and refractory patients with renal impairment. There were 3 cohorts in this trial; patients with moderate renal impairment (A), severe renal impairment (B) and severe impairment requiring haemodialysis…
Denosumab for myeloma bone disease: ready for prime time? Dimopoulos MA et al. Lancet Oncol. 2018 Feb 8. pii: S1470-2045(18)30075-5. doi: 10.1016/S1470-2045(18)30075-5. [Epub ahead of print]. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Raje N et al. Lancet Oncol. 2018 Feb 8. pii: S1470-2045(18)30072-X. doi: 10.1016/S1470-2045(18)30072-X. [Epub ahead of…
Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression.
Fernández de Larrea C et al. Leukemia. 2018 Feb 2. doi: 10.1038/s41375-018-0013-4. [Epub ahead of print].
CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience. Frerichs KA et al.Expert Rev Clin Immunol. 2018 Feb 21. doi: 10.1080/1744666X.2018.1443809. [Epub ahead of print]. Multinucleated giant myeloma cells after failure of daratumumab therapy. Guijarro F et al. Br J Haematol. 2018 Feb 22. doi: 10.1111/bjh.15139. [Epub ahead of print]. Defining a set of standardised outcome measures for newly diagnosed patients…
FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma. Pulte ED et al. Oncologist. 2018 Feb 7. pii: theoncologist.2017-0440. doi: 10.1634/theoncologist.2017-0440. [Epub ahead of print]. Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. Richardson PG et al. Br J Haematol. 2018 Feb 13. doi: 10.1111/bjh.15058. [Epub…
Serum level of long noncoding RNA H19 as a diagnostic biomarker of multiple myeloma. Pan Y et al.Clin Chim Acta. 2018 Feb 19;480:199-205. doi: 10.1016/j.cca.2018.02.019. [Epub ahead of print]. Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients With Multiple MyelomaWith Deep Responses. Miyazaki K et al. Clin Lymphoma Myeloma Leuk. 2018 Feb 19. pii: S2152-2650(17)31288-0. doi: 10.1016/j.clml.2018.01.008.…
Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone. Tanimura A et al. Int J Hematol. 2018 Jan 31. doi: 10.1007/s12185-018-2408-4. [Epub ahead of print]. Phase 1/2 Trial of Carfilzomib Plus High Dose Melphalan Preparative Regimen for Salvage AHCT Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. Costa LJ et al. Biol Blood…
Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis. Shah C et al. Leuk Lymphoma. 2018 Feb 21:1-13. doi: 10.1080/10428194.2018.1437269. [Epub ahead of print]. Acquired factor V deficiency in a patient with myeloma and amyloidosis. Quek JKS et al. Thromb Res. 2018 Jan 31;164:1-3. doi: 10.1016/j.thromres.2018.01.045. [Epub ahead of print]. Community-acquired respiratory infections are common in patients with non-Hodgkin lymphoma and multiple myeloma. Lavi N et…
Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing. Gralewski JH et al. Diagn Pathol. 2018 Feb 20;13(1):15. doi: 10.1186/s13000-018-0692-1. The transmembrane protein TMEPAI induces myeloma cell apoptosis by promoting degradation of the c-Maf transcription factor. Du Y et al. J Biol Chem. 2018 Feb 21. pii: jbc.RA117.000972. doi: 10.1074/jbc.RA117.000972. [Epub ahead of print]. Loss of heterozygosity…
The results from the Phase III ALCYONE trial have recently been published in The New England Journal of Medicine. The study compared daratumumab (Darzalex®) in combination with bortezomib (Velcade®), melphalan and prednisone (VMP) to VMP alone in newly diagnosed myeloma patients, ineligible for a stem cell transplant. The results show that the 18-month progression-free survival…